OBJECTIVES: To determine wild-type minimum inhibitory concentration (MIC) distributions for Mycobacterium tuberculosis, as the background data for defining susceptibility breakpoints are limited. METHODS: We determined wild-type MIC distributions of M. tuberculosis using a 96-stick replicator in Middlebrook 7H10 (7H10) medium for ethionamide (ETH), prothionamide, thiacetazone, cycloserine, rifabutin (RFB), clofazimine and linezolid in consecutive susceptible clinical isolates (n = 78). RESULTS: Tentative epidemiological wild-type cut-offs (ECOFF) were determined for all investigated drugs where World Health Organization recommended critical concentrations for 7H10 are lacking, except for ETH. As the ECOFF was closely related to the non-wild-type strains for ETH and thiacetazone, the use of an intermediary (I) category in drug susceptibility testing could increase reproducibility. The cross-resistance between ETH and isoniazid was 21%. Applying 0.5 mg/l as a breakpoint for RFB classified two non-wild type and rpoB mutated isolates as susceptible for RFB and resistant against rifampicin. CONCLUSIONS: We propose that wild-type MIC distributions should be used as a tool to define clinical breakpoints against second-line drugs. This is increasingly important considering the rapid emergence of drug resistance.
OBJECTIVES: To determine wild-type minimum inhibitory concentration (MIC) distributions for Mycobacterium tuberculosis, as the background data for defining susceptibility breakpoints are limited. METHODS: We determined wild-type MIC distributions of M. tuberculosis using a 96-stick replicator in Middlebrook 7H10 (7H10) medium for ethionamide (ETH), prothionamide, thiacetazone, cycloserine, rifabutin (RFB), clofazimine and linezolid in consecutive susceptible clinical isolates (n = 78). RESULTS: Tentative epidemiological wild-type cut-offs (ECOFF) were determined for all investigated drugs where World Health Organization recommended critical concentrations for 7H10 are lacking, except for ETH. As the ECOFF was closely related to the non-wild-type strains for ETH and thiacetazone, the use of an intermediary (I) category in drug susceptibility testing could increase reproducibility. The cross-resistance between ETH and isoniazid was 21%. Applying 0.5 mg/l as a breakpoint for RFB classified two non-wild type and rpoB mutated isolates as susceptible for RFB and resistant against rifampicin. CONCLUSIONS: We propose that wild-type MIC distributions should be used as a tool to define clinical breakpoints against second-line drugs. This is increasingly important considering the rapid emergence of drug resistance.
Authors: Michaela Projahn; Claudio U Köser; Susanne Homolka; David K Summers; John A C Archer; Stefan Niemann Journal: Antimicrob Agents Chemother Date: 2011-06-27 Impact factor: 5.191
Authors: Kelly E Dooley; Ekwaro A Obuku; Nadza Durakovic; Vera Belitsky; Carole Mitnick; Eric L Nuermberger Journal: J Infect Dis Date: 2012-07-17 Impact factor: 5.226
Authors: Russell R Kempker; M Tobias Heinrichs; Ketino Nikolaishvili; Irina Sabulua; Nino Bablishvili; Shota Gogishvili; Zaza Avaliani; Brent P Little; Adam Bernheim; Hartmut Derendorf; Henry M Blumberg; Sergo Vashakidze; Charles A Peloquin Journal: Eur Respir J Date: 2018-02-07 Impact factor: 16.671
Authors: Keertan Dheda; Laura Lenders; Gesham Magombedze; Shashikant Srivastava; Prithvi Raj; Erland Arning; Paula Ashcraft; Teodoro Bottiglieri; Helen Wainwright; Timothy Pennel; Anthony Linegar; Loven Moodley; Anil Pooran; Jotam G Pasipanodya; Frederick A Sirgel; Paul D van Helden; Edward Wakeland; Robin M Warren; Tawanda Gumbo Journal: Am J Respir Crit Care Med Date: 2018-11-01 Impact factor: 21.405
Authors: Kristian Ängeby; Pontus Juréen; Gunnar Kahlmeter; Sven E Hoffner; Thomas Schön Journal: Bull World Health Organ Date: 2012-05-29 Impact factor: 9.408